Wattana Sukeepaisarnjaroen
Overview
Explore the profile of Wattana Sukeepaisarnjaroen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lau G, Abou-Alfa G, Cheng A, Sukeepaisarnjaroen W, Dao T, Kang Y, et al.
J Hepatol
. 2024 Aug;
82(2):258-267.
PMID: 39089633
Background & Aims: In the global, phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) improved overall survival (OS) vs. sorafenib; durvalumab was non-inferior...
2.
Mohamed R, Wang W, Tanwandee T, Hasan I, Pham C, Lim Y, et al.
J Gastrointest Cancer
. 2024 Jul;
55(3):1333-1344.
PMID: 38995318
Purpose: In several Asian countries, hepatocellular carcinoma (HCC) is a leading cause of cancer deaths. HCC risk factors in Asia differ from those elsewhere and are changing with the treatment...
3.
Pupacdi B, Loffredo C, Budhu A, Rabibhadana S, Bhudhisawasdi V, Pairojkul C, et al.
Int J Cancer
. 2024 May;
155(8):1387-1399.
PMID: 38761410
Thailand is among countries with the highest global incidence and mortality rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). While viral hepatitis and liver fluke infections have been associated...
4.
Prechaporn W, Hantrakul P, Ngamjarus C, Sukeepaisarnjaroen W, Sawanyawisuth K, Khamsai S
Heart Fail Rev
. 2024 May;
29(4):811-826.
PMID: 38722388
Obstructive sleep apnea (OSA) is a disease with intermittent hypoxemia during sleep. It has been shown that OSA is related to several cardiovascular diseases including heart failure. Both OSA and...
5.
Kohler B, Bes M, Chan H, Esteban J, Piratvisuth T, Sukeepaisarnjaroen W, et al.
Int J Biol Markers
. 2024 Mar;
39(2):107-117.
PMID: 38549363
Introduction: Diagnosis of cholangiocarcinoma (CCA) can be challenging due to unclear imaging criteria and difficulty obtaining adequate tissue biopsy. Although serum cancer antigen 19-9 and carcinoembryonic antigen have been proposed...
6.
Sriphoosanaphan S, Pantumongkol W, Kulpeng W, Charonpongsuntorn C, Tanwandee T, Sukeepaisarnjaroen W, et al.
PLoS One
. 2024 Mar;
19(3):e0300327.
PMID: 38512900
Background: Clinical trials have proven the efficacy and safety of atezolizumab combined with bevacizumab (A+B) in treating unresectable hepatocellular carcinoma (uHCC). This study aimed to assess the cost-utility of A+B...
7.
Yau T, Kaseb A, Cheng A, Qin S, Zhu A, Chan S, et al.
Lancet Gastroenterol Hepatol
. 2024 Feb;
9(4):310-322.
PMID: 38364832
Background: The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab...
8.
Abou-Alfa G, Lau G, Kudo M, Chan S, Kelley R, Furuse J, et al.
NEJM Evid
. 2024 Feb;
1(8):EVIDoa2100070.
PMID: 38319892
BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed...
9.
Do W, Wang L, Forgues M, Liu J, Rabibhadana S, Pupacdi B, et al.
Cell Rep Med
. 2023 Dec;
4(12):101328.
PMID: 38118412
This study evaluates the pan-serological profiles of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) compared to several diseased and non-diseased control populations to identify risk factors and biomarkers of liver...
10.
Kohansal-Nodehi M, Lange M, Kroeniger K, Rolny V, Tabares G, Piratvisuth T, et al.
Front Oncol
. 2023 Nov;
13:1213898.
PMID: 37920152
Background: There is a need for new serum biomarkers for early detection of hepatocellular carcinoma (HCC). Haptoglobin (Hp) N-glycosylation is altered in HCC, but the diagnostic value of site-specific Hp...